derstanding pathogenetic mechanisms and development of advances in phar- macologic management of rheumatic diseases, ranging from methotrexate and biological agents in rheumatoid arthritis (RA) (7) to cyclophosphamide and mycophenolate mofetil in systemic lupus erythematosus (SLE) nephritis

1Division of Rheumatology, NYU Hospital for Joint Diseases, New York; 2Clinical Professor of Medicine, New York University School of Medicine, and Director of Outcomes Research, NYU Hospital for Joint Diseases, New York, USA. Benjamin Abelson, BA Ann Rupel, BA Theodore Pincus, MD Please address correspondence to: Theodore Pincus, MD, Division of Rheumatology NYU Hospital for Joint Diseases, 301 East 17th Street, Room 1608, New York, NY 10003, USA. E-mail: [email protected] Received and accepted on September 19, 2008. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S25-S34. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2008.